Siegfried Holding (SFZN) Stock Overview
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SFZN Community Fair Values
See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Siegfried Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 66.90 |
| 52 Week High | CHF 101.60 |
| 52 Week Low | CHF 68.50 |
| Beta | 0.79 |
| 1 Month Change | -15.21% |
| 3 Month Change | -11.39% |
| 1 Year Change | -28.45% |
| 3 Year Change | -7.85% |
| 5 Year Change | -20.59% |
| Change since IPO | 780.26% |
Recent News & Updates
SFZN: Raised 2026 Sales Guidance Will Support Future Rerating Potential
Analysts have reduced the fair value estimate for Siegfried Holding from CHF 136.00 to CHF 126.00, citing updated assumptions on discount rates, revenue growth, profit margins and the future P/E multiple that align with recent Street research, including a CHF 4 price target adjustment. What's in the News Siegfried AG raised its earnings guidance for 2026, now expecting high single digit % growth in group net sales in local currencies, compared with its previous outlook for low single digit % growth.SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside
Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment.SFZN: Lowered Expectations And 2026 Guidance Shift Will Support Future Upside Potential
Narrative Update: Siegfried Holding Analysts have adjusted their average price target for Siegfried Holding to CHF 103.91, a change of roughly CHF 0.69. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions informed by the recent mix of higher and lower CHF targets from the Street.SFZN: Fair Value Reset Will Put Greater Emphasis On Execution Risks
Analysts now see fair value for Siegfried Holding at CHF 85.00, down from CHF 90.00. This aligns with recent price target cuts, such as the move from CHF 108 to CHF 96, and reflects updated assumptions on growth, profitability and discount rates.Recent updates
Shareholder Returns
| SFZN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -13.9% | -0.2% | 2.5% |
| 1Y | -28.4% | -10.1% | 11.0% |
Return vs Industry: SFZN underperformed the Swiss Life Sciences industry which returned -10.1% over the past year.
Return vs Market: SFZN underperformed the Swiss Market which returned 11% over the past year.
Price Volatility
| SFZN volatility | |
|---|---|
| SFZN Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: SFZN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1873 | 3,891 | Marcel Imwinkelried | www.siegfried.ch |
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition.
Siegfried Holding AG Fundamentals Summary
| SFZN fundamental statistics | |
|---|---|
| Market cap | CHF 3.17b |
| Earnings (TTM) | CHF 168.66m |
| Revenue (TTM) | CHF 1.33b |
Is SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFZN income statement (TTM) | |
|---|---|
| Revenue | CHF 1.33b |
| Cost of Revenue | CHF 973.84m |
| Gross Profit | CHF 353.99m |
| Other Expenses | CHF 185.34m |
| Earnings | CHF 168.66m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | 3.85 |
| Gross Margin | 26.66% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 51.0% |
How did SFZN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 17:34 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siegfried Holding AG is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Vineet Agrawal | Citigroup Inc |